JP2005047906A - Anti-inflammatory/analgesic composition for external application - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a highly effective anti-inflammatory/analgesic composition for external application by increasing skin permeability of a nonsteroidal anti-inflammatory/analgesic agent. <P>SOLUTION: The anti-inflammatory/analgesic composition for external application contains the nonsteroidal anti-inflammatory/analgesic agent and a starch powder. The nonsteroidal anti-inflammatory/analgesic agent is used for chronic rheumatism, osteoarthritis and acute and chronic musculoskeletal pains but generally has a side effect such as gastrointestinal injury. Therefore, various formulations other than oral agents such as external preparations and suppositories have been developed and used for medical practice. The present invention solves the problem associated with the external preparations wherein satisfactory effects could not be achieved due to a marked deterioration in the skin permeability of the drug induced by a biological barrier effect of keratin. <P>COPYRIGHT: (C)2005,JPO&NCIPI

Description

  The present invention relates to an external anti-inflammatory analgesic composition having an increased skin permeability of medicinal ingredients.

  Non-steroidal anti-inflammatory analgesics are used for rheumatoid arthritis, osteoarthritis, musculoskeletal acute and chronic pain, and the like. However, since it generally has side effects such as gastrointestinal disorders, various dosage forms such as external preparations and suppositories have been developed in addition to oral preparations and have been used in the medical field. However, in the case of an external preparation, since the skin permeability of the drug is remarkably suppressed by the effect of the biological barrier due to the keratin, there are cases where a satisfactory effect cannot be obtained.

  Conventionally, a percutaneous absorption enhancer has been studied in order to increase the skin permeability of a drug. For example, nicotinic acid ester (patent document 1), lactic acid and polyoxyethylene alkyl ether phosphate and lauric acid diethanolamine salt (patent document 2), ethylene oxide addition type nonionic surfactant (patent document 3), polyoxy Ethylene alkyl ether agents and polyoxyethylene phenyl ether agents (Patent Document 4), 1- [2- (decylthio) ethyl] azacyclopentan-2-one and cyclodextrins (Patent Document 5), polyoxyethylene derivatives and polyethylene Glycol (Patent Document 6), polyethylene glycol stearate or further polyoxysorbitan stearate (Patent Document 7), alkylene glycol derivative, 1-alkylazacycloheptan-2-one, fatty acid and derivatives thereof, fatty acid alkanolamide Class And polyethylene glycol derivatives (Patent Document 8), epezoline or tolperisone (Patent Document 9), 1-alkylazacycloheptan-2-one and cis-olefin compounds (Patent Documents 10 and 11), N-substituted morpholine (Patent Document 12) ) And absorption accelerator blending techniques such as oleates (Patent Document 13) are disclosed.

  In addition, a percutaneous absorption enhancer containing a powder that increases the longitudinal relaxation time of the NMR spectrum of the oil as an active ingredient is also known (Patent Document 14).

  However, when these percutaneous absorption enhancers are blended, adding a sufficient amount of the percutaneous absorption enhancer to produce an effect is still satisfactory because it tends to cause skin irritation and the effect is insufficient. It was not possible.

  Furthermore, a skin-type external preparation for skin application is disclosed in which a relatively large amount of a polyhydric alcohol, a polymer compound and solid particles are blended in the preparation to enhance the feeling of use (Patent Document 15). However, this technique is troublesome because it requires rubbing after application, and has a drawback that if it is not wiped off after application, it will stain the clothes.

  Further, an external preparation is disclosed in which the percutaneous absorbability of the drug is enhanced by blending scrub (Patent Document 16). However, this technique has a problem that the scrub is a particulate matter that peels off the stratum corneum of the skin or causes minute scratches, so that it is likely to cause skin irritation and the feeling of use is poor.

On the other hand, it is known to add starch powder to cosmetics, but the effect is expected to be smooth. It is also known that starch is added to an external preparation, but it is characterized by having a viscosity as a thickener or easily washed off after forming a hydrogel to protect the affected area. No proposal has been made regarding the skin absorbability of natural anti-inflammatory analgesics. (Patent Documents 17 to 19)
JP-A 61-27920 JP-A-5-186371 JP-A-6-279289 JP 58-79918 JP-A-4-275235 Japanese Unexamined Patent Publication No. 4-103528 Japanese Patent Laid-Open No. 10-87494 Japanese National Patent Publication No. 8-500365 JP 2000-143510 A Japanese Patent Publication No. 7-57725 Japanese Patent Publication No.7-68147 Japanese Patent Laid-Open No. 2-59528 JP-A-63-313731 Japanese Patent Laid-Open No. 11-189545 Japanese Patent Laid-Open No. 2003-81881 Japanese Patent Laid-Open No. 11-80031 Japanese Patent Laid-Open No. 10-182348 JP-A-51-142526 JP 2001-97848 A

  An object of the present invention is to provide an external anti-inflammatory analgesic composition that exhibits an excellent effect by increasing the skin permeability of a non-steroidal anti-inflammatory analgesic.

  As a result of intensive investigations to solve such problems, the present inventors have promoted the skin permeability of nonsteroidal anti-inflammatory analgesics when a certain powder component is added and dispersed in the composition. As a result, the present invention has been completed.

  That is, the present invention is a topical anti-inflammatory analgesic composition comprising a non-steroidal anti-inflammatory analgesic and starch powder.

  According to the present invention, it is possible to provide an external anti-inflammatory analgesic composition in which the skin permeability of a non-steroidal anti-inflammatory analgesic is increased.

  Nonsteroidal anti-inflammatory analgesics effective in the present invention are indomethacin, piroxicam, ampiroxicam, meloxicam, lornoxicam, suprofen, bufexamac, bendazac, ufenamate, ketoprofen, ibuprofen, ibuprofen piconol, flurbiprofen, naproxen, loxoprofen , Aluminoprofen, felbinac, diclofenac sodium, sulindac, flufenamic acid, mefenamic acid, tolfenamic acid, glycyrrhetinic acid and salts thereof, glycyrrhizic acid and salts thereof, glycolic salicylate, methyl salicylate, etc., with indomethacin or piroxicam being particularly preferred .

  In the present invention, the blending amount of the non-steroidal anti-inflammatory analgesic is preferably 0.1 to 20% by mass, more preferably 0.5 to 5% by mass based on the entire preparation. However, it can be appropriately changed depending on the dosage form and the type and amount of the nonsteroidal anti-inflammatory analgesic.

  Among the starch powders used in the present invention, preferred starch powders include corn starch, potato starch and wheat starch.

  Although the mechanism of action for promoting percutaneous absorption of the present invention is unclear, use of zinc oxide having a skin astringent action significantly suppresses percutaneous absorption. It is considered to be specific to the combination of starch powder.

  About the compounding quantity of starch powder, 0.1-10 mass% of the whole formulation is preferable, and 0.1-7 mass% is the most preferable. If the amount is less than 0.1% by mass, the effect of promoting transdermal absorption of the nonsteroidal anti-inflammatory analgesic agent is not sufficient, and if it exceeds 10% by mass, the properties of the preparation are greatly affected and the feeling of use is reduced. .

  The average particle size of the starch powder used in the present invention is preferably 0.001 to 100 μm, particularly preferably 1 to 50 μm. The starch powder is preferably finer, but fine particles of 0.001 μm or less are difficult to produce, and if it is 100 μm or more, a rough feeling may occur after the formulation is applied.

  In the present invention, no particular rubbing is required, and percutaneous absorption is promoted.

  The anti-inflammatory analgesic composition for external use of the present invention can be prepared as a liquid preparation such as cream, ointment, lotion, semi-solid preparation such as gel, aerosol, tic, etc. The gel is most preferable from the viewpoint of dispersion and retention in the gel and the feeling of use. These can be produced by conventional methods.

  Here, the gel agent is a commonly used gelling agent (alginic acid, propylene glycol alginate, ethyl cellulose, methyl cellulose, carboxyvinyl polymer, acrylic acid / alkyl methacrylate copolymer, carbomer, carboxymethyl cellulose, xanthan gum, carrageenan, hydroxy Propylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydrophobized hydroxypropylmethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, aluminum stearate, dextran fatty acid ester, salts and derivatives thereof, etc. can be used Preferred from the properties of the gel are carboxyvinyl polymer and alkyl-modified carbo One or more selected from the group consisting of civinyl polymer, polyvinylpyrrolidone, hydroxypropylmethylcellulose, hydrophobized hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, carboxymethylcellulose or a salt thereof, alginic acid or a salt thereof, xanthan gum and carrageenan Among these, one or more selected from carboxyvinyl polymer, hydroxypropylmethylcellulose, hydroxyethylcellulose and hydrophobized hydroxypropylmethylcellulose are most preferable.

  The viscosity of the gel used for producing the gel preparation in the present invention is preferably 30 mPa · s to 5000 mPa · s, and most preferably 100 mPa · s to 500 mPa · s in view of the usability such as ease of application.

  Moreover, when mix | blending a polyhydric alcohol with the external anti-inflammatory analgesic composition of this invention, the compounding quantity has preferable 20 mass% or less of the whole formulation. This is because when it exceeds 20% by mass, not only the feeling when applied but also the clothes, bedding, etc. are soiled if not wiped off after being applied to the skin.

  The liquid preparation can also be prepared according to a conventional method. For example, after dissolving a non-steroidal anti-inflammatory analgesic in a liquid such as a lower alcohol, a polyhydric alcohol, water or a mixed solution thereof, starch powder is dispersed. can get. When an appropriate gelling agent is blended with the liquid obtained here, a gel can be obtained. The starch powder may be added before or after the gelling agent is added.

It is preferable from the viewpoint of medicinal effect that the anti-inflammatory analgesic composition for external use of the present invention contains a drug capable of improving symptoms such as rheumatoid arthritis, osteoarthritis and musculoskeletal acute / chronic pain in addition to the ingredients. Examples of such drugs include camphor, turpentine oil, mint oil, menthol and derivatives thereof, eucalyptus oil, refreshing agents such as menthyl lactate, local irritants such as nonylic acid vanillylamide and capsaicin, anti-inflammatory agents such as glycyrrhizic acid, Diphenylimidazole, diphenhydramine and its salts, antihistamines such as chlorpheniramine maleate, blood circulation promoters such as tocopherol acetate and benzyl nicotinate, arnica tincture, agaric extract, sushi extract, horse chestnut extract, funnel extract, belladonna extract, toki extract, Herbal medicines such as coconut extract, salamander extract, and pepper extract are listed.

  In the external anti-inflammatory analgesic composition of the present invention, various base components that can be blended with pharmaceuticals and quasi-drugs can be blended within a range that does not impair the effects of the present invention.

Example 1: 0.5 g of gel piroxicam
Ethanol 30g
Propylene glycol 15g
Carboxyvinyl polymer 1.0g
pH adjuster appropriate amount corn starch 7.0g
100g of purified water
After swelling carboxyvinyl polymer in purified water, add propylene glycol, add ethanol solution in which piroxicam is dissolved, pH adjuster, mix uniformly, add corn starch dispersed in ethanol, The mixture was mixed so as to be uniformly dispersed to obtain a gel.

Example 2: Gel agent piroxicam 0.5 g
l-Menthol 3.0g
Ethanol 45g
1,3-butylene glycol 10g
Carboxy vinyl polymer 0.5g
Hydroxypropyl methylcellulose 0.5g
pH adjuster appropriate amount corn starch 0.5g
100g of purified water
A carboxyvinyl polymer and hydroxypropylmethylcellulose were swollen in purified water, 1,3-butylene glycol was added, and an ethanol solution in which a pH adjuster, piroxicam, and 1-menthol were dissolved was added and mixed uniformly. Further, corn starch dispersed in ethanol was added and mixed so as to be uniformly dispersed to obtain a gel.

Example 3: Gel Indomethine 1.0 g
Ethanol 40g
Propylene glycol 15g
Carboxyvinyl polymer 1.0g
pH adjuster appropriate amount corn starch 7.0g
100g of purified water
After swelling the carboxyvinyl polymer in purified water, propylene glycol was added, and a pH adjuster dissolved in purified water was added to cause gelation. A separately prepared ethanol solution in which indomethacin was dissolved was added and mixed to be uniform, and then corn starch dispersed in ethanol was added and mixed to be uniformly dispersed to obtain a gel.

Example 4: Gel agent indomethacin 1.0 g
Ethanol 70g
1,3-butylene glycol 5g
Carboxyvinyl polymer 1.0g
pH adjuster appropriate amount corn starch 0.5g
100g of purified water
After swelling the carboxyvinyl polymer in purified water, 1,3-butylene glycol was added, and a pH adjuster dissolved in purified water was added to cause gelation. A separately prepared ethanol solution in which indomethacin was dissolved was added and mixed to be uniform, and then corn starch dispersed in ethanol was added and mixed to be uniformly dispersed to obtain a gel.

Example 5: 0.5 g of gel agent piroxicam
Ethanol 40g
Propylene glycol 15g
Carboxyvinyl polymer 1.0g
pH adjuster appropriate amount potato starch 7.0g
100g of purified water
After swelling the carboxyvinyl polymer in purified water, add propylene glycol and water, add separately prepared piroxicam and ethanol solution in which pH adjuster is dissolved, mix uniformly and then disperse in ethanol Potato starch was added and mixed to disperse uniformly to obtain a gel.

Example 6: Gel agent Piroxicam 0.5 g
Ethanol 20g
Isopropanol 20g
Propylene glycol 15g
Carboxyvinyl polymer 1.0g
pH adjuster appropriate amount wheat starch 7.0g
100g of purified water
After swelling the carboxyvinyl polymer in purified water, propylene glycol was added, and a pH adjuster dissolved in purified water was added to cause gelation. A separately prepared ethanol solution in which piroxicam was dissolved was added and mixed to be uniform, and then wheat starch dispersed in ethanol was added and mixed to be uniformly dispersed to obtain a gel.

Example 7: 0.5 g cream piroxicam
Tocopherol acetate 0.5g
l-Menthol 3.0g
dl-Camphor 0.5g
Corn starch 5.0g
Glycerin 5.0g
Polysorbate 60 2.5g
1,3-butylene glycol 10.0g
Liquid paraffin 4.0g
Squalane 4.0g
Cetostearyl alcohol 5.0 g
Benzyl alcohol 1.0g
Stearic acid 1.0g
Stearic acid monoglyceride 1.5g
Carboxy vinyl polymer 0.2g
Xanthan gum 0.1g
Dimethylpolysiloxane 0.5g
pH adjuster
L-Arginine Appropriate amount edetate salt Appropriate amount of parabens Appropriate amount Sodium pyrosulfite Appropriate amount of purified water 100g
Carboxyvinyl polymer and xanthan gum were dissolved in purified water, a drug dissolved in an aqueous component was added, and the mixture was heated to 80 ° C. while stirring with a tabletop emulsifier. An oily component that had been heated and melted in advance was added thereto from the hopper and cooled to 50 ° C. After homogenizing at 8000 rpm for 3 minutes and homogenizing, corn starch dispersed in an aqueous component was added from a hopper and cooled to room temperature while stirring with a scraping mixer. Finally, a pH adjuster was added to gel and a cream was prepared.

Example 8: 1.0 g of gel indomethacin
l-Menthol 3.0g
Tocopherol acetate 0.5g
Corn starch 2.0g
Octyldodecyl myristate 5.0g
Sorbitan monostearate 2.0g
Polysorbate 60 2.0g
Glycerol monostearate 1.0g
Diisopropyl adipate 3.0g
Hydroxypropyl methylcellulose 0.5g
Carboxy vinyl polymer 0.5g
Isopropanol 36g
Edetate appropriate amount sodium bisulfite appropriate amount pH adjuster appropriate amount purified water 100g
Carboxyvinyl polymer, hydroxypropyl methylcellulose was swollen in purified water, heated to 80 ° C. with stirring, oily components and drugs that had been preheated and melted were added from the hopper, and cooled to 50 ° C. . After the aqueous component was added and homogenized, corn starch dispersed in isopropanol was added from a hopper, cooled to room temperature while stirring with a scraping mixer, and finally a pH adjuster was added to prepare a gel.

Example 9: Lotion preparation Piroxicam 0.5 g
l-Menthol 3.0g
Tocopherol acetate 0.5g
dl-Camphor 0.5g
Corn starch 1.0g
1,3-Butylene glycol 5.0g
Benzyl alcohol 1.0g
Purified water 20.0g
Polysorbate 80 2.0g
Sodium bisulfite Appropriate edetate Appropriate dibutylhydroxytoluene Appropriate ethanol Total 100 mL
Among the above components, components other than corn starch were stirred and dissolved uniformly, and then corn starch was added to prepare a liquid for external use.

Example 10: Lotion agent Piroxicam 0.5 g
l-Menthol 3.0g
Tocopherol acetate 0.5g
Corn starch 3.0g
1,3-Butylene glycol 5.0g
Benzyl alcohol 1.0g
Purified water 20.0g
Polysorbate 80 2.0g
Sodium bisulfite appropriate amount edetate appropriate amount dibutylhydroxytoluene appropriate amount ethanol 20mL
100 ml of isopropanol
Among the above components, components other than corn starch were stirred and dissolved uniformly, and then corn starch was added to prepare a liquid for external use.

Example 11: Lotion agent Piroxicam 0.5 g
l-Menthol 3.0g
Tocopherol acetate 0.5g
Corn starch 5.0g
Purified water 20.0g
Polysorbate 60 1.0g
Sodium bisulfite Appropriate edetate Appropriate dibutylhydroxytoluene Appropriate ethanol Total 100 mL
Among the above components, components other than corn starch were stirred and dissolved uniformly, and then corn starch was added to prepare a liquid for external use.

Example 12: Gel agent After adding 0.5 g of carboxyvinyl polymer and 0.5 g of hydroxypropylmethylcellulose to the lotion obtained in Example 9, the gel was prepared by adding an appropriate amount of a pH adjuster.

Example 13: Gel agent After adding 0.5 g of carboxyvinyl polymer and 1.0 g of hydroxypropylmethylcellulose to the lotion obtained in Example 9, the gel was prepared by adding an appropriate amount of a pH adjuster.

Example 14: Gel Agent After adding 0.5 g of carboxyvinyl polymer and 0.5 g of hydroxypropylmethylcellulose to the lotion obtained in Example 10, the gel was prepared by adding an appropriate amount of a pH adjuster.

Example 15: Gel Agent A gel agent was prepared by further adding 1.0 g of carboxyvinyl polymer and 0.5 g of hydroxypropylmethylcellulose to the lotion obtained in Example 10 and dissolving it, and then adding an appropriate amount of a pH adjuster.

Example 16: Gel agent After adding 0.5 g of carboxyvinyl polymer and 0.5 g of hydroxypropylmethylcellulose to the lotion obtained in Example 11, the gel was prepared by adding an appropriate amount of a pH adjuster.

Example 17: Gel agent After adding 0.5 g of carboxyvinyl polymer and 1.0 g of hydroxypropylmethylcellulose to the lotion obtained in Example 11, a gel was prepared by adding an appropriate amount of a pH adjuster.

Example 18: Gel agent To the lotion obtained in Example 9, 1.0 g of hydroxyethyl cellulose was further added and dissolved to prepare a gel agent.

Example 19: Gelling agent 1.0 g of hydrophobized hydroxypropylmethylcellulose was further added to the lotion obtained in Example 11 and dissolved to prepare a gelling agent.

Example 20: Aerosol Agent An aerosol agent was prepared by putting 40% of the lotion agent of Example 9 and 60% of dimethyl ether gas into a pressure vessel made of aluminum.

Example 21: Aerosol Agent An aerosol agent was prepared by putting 40% of the lotion agent of Example 10 and 60% of a liquefied petroleum gas / dimethyl ether mixed gas into a pressure vessel made of aluminum.

Example 22: Aerosol Agent An aerosol agent was prepared by putting 40% of the lotion agent of Example 11 and 60% of dimethyl ether gas into an aluminum pressure vessel.

Example 23: 0.5 g of tic agent piroxicam
l-Menthol 3.0g
Tocopherol acetate 0.5g
Corn starch 4.0g
1,3-butylene glycol 25.0g
Benzyl alcohol 1.0g
Purified water 5.0g
Polysorbate 80 1.0g
Glycerol monostearate 1.0g
Hydroxypropyl methylcellulose 0.5g
Sodium stearate 10.0g
Sodium bisulfite appropriate amount edetate appropriate amount ethanol 100g
After the above components were dissolved by heating, they were filled into a cylindrical container, cooled to room temperature by slow cooling to such an extent that corn starch did not settle, and solidified to prepare a tic agent.

Example 24: Ointment piroxicam 0.5 g
Glycyrrhetinic acid 0.02g
l-Menthol 3.0g
Tocopherol acetate 0.5g
Corn starch 10.0g
White petrolatum 20.0g
Dextrin palmitate 15.0g
Dimethylpolysiloxane 0.05g
100g liquid paraffin
After the oil component and the drug were uniformly dissolved or dispersed while heating, corn starch was added and gradually cooled to room temperature while stirring well to prepare an ointment.

  With the formulations shown in the following table, gel agents of Examples and Comparative Examples were produced by ordinary methods.

(Test Example 1) Rat Percutaneous Permeability Test (Method)
Skin was extracted from the left and right sides of the abdominal shaved part of a hairless rat (male, 8 to 10 weeks old) shaved with an electric shaver. After applying the extracted skin to a horizontal diffusion cell with an average effective area of 0.98 cm ² , apply a fixed amount of each sample shown in Table 1 in the cell on the donor side to cover the sample so that it does not evaporate. 3 mL of pH 7.4 phosphate buffer was added to the cell. Constant temperature water at 37 ° C. was refluxed to the outer layer of the receiver layer, and the receiver liquid was stirred with a stirring bar.

  A fixed amount of the receiver solution was collected over time, and the drug amount was measured by high performance liquid chromatography using piroxicam 255 nm, indomethacin 254 nm, and internal standard substances propyl paraoxybenzoate and heptyl paraoxybenzoate.

  The results of the skin permeability test of the piroxicam formulation are shown in FIG. In Example 1, the skin permeability of piroxicam was remarkably increased by adding starch powder as compared with Comparative Example 1.

  In addition, FIG. 2 shows the cumulative permeation amount of piroxicam after 10 hours in each comparative example and Example 1 when the cumulative permeation amount after 10 hours of Comparative Example 1 is 100%. It can be seen that Example 1 is increased by the formulation of starch powder.

  The results of the skin permeability test of the indomethacin combination preparation are shown in FIG. By blending starch powder, skin permeability of indomethacin increased dramatically in Example 3 as compared with Comparative Example 5.

  In addition, FIG. 4 shows indomethacin cumulative permeation amount after 10 hours in each comparative example and Example 3 when the cumulative permeation amount after 10 hours of Comparative Example 5 is 100%. It can be seen that Example 3 is increased by the addition of starch powder.

It is the figure which showed the measurement result of the piroxicam accumulation | transmission amount of Example 1 and Comparative Example 1, and the accumulation amount (microgram / cm < ² >) was shown on the vertical axis | shaft and time was shown on the horizontal axis. (Average of hairless rats n = 3-4) It is the figure which showed the measurement result (average of hairless rat n = 3-4) of each comparative example and the piroxicam cumulative permeation amount of Example 1 when the cumulative permeation amount after 10 hours of Comparative Example 1 was 100%. . It is the figure which showed the measurement result of the indomethacin cumulative permeation amount of Example 3 and Comparative Example 5, the cumulative permeation amount (μg / cm ² ) on the vertical axis, and the time on the horizontal axis. (Average of hairless rats n = 3-4) It is the figure which showed the measurement result (average of hairless rat n = 3-4) of each comparative example and indomethacin cumulative permeation amount of Example 3 when the cumulative permeation amount after 10 hours of Comparative Example 5 was taken as 100%. .

Claims (10)

A topical anti-inflammatory analgesic composition comprising a non-steroidal anti-inflammatory analgesic and starch powder. The external anti-inflammatory analgesic composition according to claim 1, wherein the non-steroidal anti-inflammatory analgesic is piroxicam. The external anti-inflammatory analgesic composition according to claim 1, wherein the non-steroidal anti-inflammatory analgesic is indomethacin. The external anti-inflammatory analgesic composition according to claim 1, wherein the amount of the non-steroidal anti-inflammatory analgesic is 0.1 to 20% by mass of the whole preparation. 2. The anti-inflammatory analgesic composition for external use according to claim 1, wherein the compounding amount of the starch powder is 0.1 to 10% by mass of the whole preparation. The external anti-inflammatory analgesic composition according to claim 1, wherein the starch powder is one or more selected from the group consisting of corn starch, potato starch, and wheat starch. It is a gel agent, The external anti-inflammatory analgesic composition in any one of Claims 1-6. Selected from the group consisting of carboxyvinyl polymer, alkyl-modified carboxyvinyl polymer, polyvinylpyrrolidone, hydroxypropylmethylcellulose, hydrophobized hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, carboxymethylcellulose or salt thereof, alginic acid or salt thereof, xanthan gum and carrageenan The anti-inflammatory analgesic composition for external use according to claim 7, wherein the composition is gelled by one or more kinds. A non-steroidal external anti-inflammatory analgesic skin absorption enhancer characterized by comprising starch powder. An external anti-inflammatory analgesic composition comprising starch powder in a dispersed state, wherein the starch powder promotes skin absorption of a non-steroidal external anti-inflammatory analgesic.

Images